Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers

Rau, Kun‐Ming; Huang, Chao‐Cheng; Chiu, Tai‐Jan; Chen, Yen‐Yang; Lu, Chun‐Wei; Liu, Chien-Ting; Pei, Sung‐Nan; Wei, Yu‐Ching

doi:10.3892/etm.2012.594

Cited by 22 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were also demonstrated in other studies that MVD of CD31 did not correlate with clinical outcome (Honkoop et al, 1998;Mayers et al, 1998;Charpin et al, 2004). MVD determined by CD105 was found to predict disease free survival in patients with stage I and II diseases whereas only hormone receptors were found to correlate with overall survival in patients with stage III disease (Rau et al, 2012). However,vascular invasion was reported to be a significant prognostic factor in basal and triple negative breast cancer by univariate and multivariate analyses (Mohammed et al, 2011).…”

Section: Discussionsupporting

confidence: 82%

Microvessel Density (MVD) in Locally Advanced Breast Cancer

Krishnapriya

Malipatil

Surekha

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background:The aim of this study was to evaluate microvessel density (MVD) by expression of CD31 and CLEC14A in core biopsies from previously untreated patients with locally advanced breast cancer (LABC) and assess its prognostic significance.Methods:MVD was evaluated in core needle biopsies (n = 92), collected prior to any treatment, from patients who were diagnosed with locally advanced breast cancer (LABC). Immunohistochemistry for expression of CD31 and CLEC14A were performed on these tumours. The median duration of follow-up was 9.3 years. The effect of prognostic factors on disease free survival (DFS) and overall survival (OS) was assessed using a Log rank test and Cox regression model.Results:The clinical factors such as age, clinical nodal stage, stage and pathological nodal status were found to be significant in predicting overall survival by multivariate analysis (P<0.05). Out of 92, 52 tumours had blood vessels expressing CD31, whereas in the remainder, there was no expression. The mean and median MVD of CD31 in 92 tumours was 38 and 5.5 respectively, and it was not a significant factor for predicting disease free survival or overall survival. When we considered the tumours (n=52) which expressed CD31, patients who had very high MVD (>100), had inferior progression free survival and overall survival (P=0.5). There was no expression of CLEC14A in any of the core needle biopsies whereas it was expressed in specimens from mastectomy from the same patient.Conclusion:This is the first report of MVD in LABC prior to any treatment. The results suggest angiogenesis could be a prognostic factor in LABC.

show abstract

Section: Discussionsupporting

confidence: 82%

Microvessel Density (MVD) in Locally Advanced Breast Cancer

Krishnapriya

Malipatil

Surekha

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Other typical markers of MSCs such as CD105 and CD146 could be present in this stromal cell type. Until now, the expression of CD105 and CD146 was described in endothelial progenitors [ 15 – 18 ] and pericytes [ 19 , 20 ]. Moreover, it was reported that the immunoexpression of microvessels containing CD105 or CD146-labeled endothelial cells is a marker of poor outcome in BC [ 15 – 18 ].…”

Section: Introductionmentioning

confidence: 99%

CD105 Expression on CD34-Negative Spindle-Shaped Stromal Cells of Primary Tumor Is an Unfavorable Prognostic Marker in Early Breast Cancer Patients

et al. 2015

View full text Add to dashboard Cite

Several studies have confirmed that the breast tumor microenvironment drives cancer progression and metastatic development. The aim of our research was to investigate the prognostic significance of the breast tumor microenvironment in untreated early breast cancer patients. Therefore, we analyzed the association of the expression of α-SMA, FSP, CD105 and CD146 in CD34-negative spindle-shaped stromal cells, not associated with the vasculature, in primary breast tumors with classical prognostic marker levels, metastatic recurrence, local relapse, disease-free survival, metastasis-free survival and the overall survival of patients. In the same way, we evaluated the association of the amount of intra-tumor stroma, fibroblasts, collagen deposition, lymphocytic infiltration and myxoid changes in these samples with the clinical-pathological data previously described. This study is the first to demonstrate the high CD105 expression in this stromal cell type as a possible independent marker of unfavorable prognosis in early breast cancer patients. Our study suggests that this new finding can be useful prognostic marker in the clinical-pathological routine.

show abstract

“…Recent studies have demonstrated that Cu is associated with angiogenesis (40), which is important in the proliferation, invasion and metastasis of tumor cells (41,42). Therefore, based on the biological function of Cu in tumor progression, inhibition of angiogenesis by reducing the content of Cu in vivo may be developed as a novel strategy in cancer therapy (4,43).…”

Section: Cu and Cu-based Complexesmentioning

confidence: 99%

Novel copper complexes as potential proteasome inhibitors for cancer treatment

Zhang

Wang

Yan

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

The use of metal complexes in the pharmaceutical industry has recently increased and as a result, novel metal‑based complexes have initiated an interest as potential anticancer agents. Copper (Cu), which is an essential trace element in all living organisms, is important in maintaining the function of numerous proteins and enzymes. It has recently been demonstrated that Cu complexes may be used as tumor‑specific proteasome inhibitors and apoptosis inducers, by targeting the ubiquitin‑proteasome pathway (UPP). Cu complexes have demonstrated promising results in preclinical studies. The UPP is important in controlling the expression, activity and location of various proteins. Therefore, selective proteasome inhibition and apoptotic induction in cancer cells have been regarded as potential anticancer strategies. The present short review discusses recent progress in the development of Cu complexes, including clioquinol, dithiocarbamates and Schiff bases, as proteasome inhibitors for cancer treatment. A discussion of recent research regarding the understanding of metal inhibitors based on Cu and ligand platforms is presented.

show abstract

Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers

Cited by 22 publications

References 34 publications

Microvessel Density (MVD) in Locally Advanced Breast Cancer

Microvessel Density (MVD) in Locally Advanced Breast Cancer

CD105 Expression on CD34-Negative Spindle-Shaped Stromal Cells of Primary Tumor Is an Unfavorable Prognostic Marker in Early Breast Cancer Patients

Novel copper complexes as potential proteasome inhibitors for cancer treatment

Contact Info

Product

Resources

About